Aesthetic medicine is a $29B global category with no system of record. Rinnova is the first platform built specifically for it — connecting patients, providers, and manufacturers through structured, longitudinal data.
Aesthetic treatments are fragmented across providers, undocumented in meaningful detail, and invisible to the people who receive them. No one is tracking what actually works.
People spend thousands each year but can't remember what product was used, how much, or what it cost. There's no timeline, no transparency, no continuity if they change providers.
EMRs weren't built for aesthetics. Injection details live in paper notes, Instagram DMs, or not at all. Retention depends on staff remembering to text each client.
Allergan, Galderma, Merz — they sell billions in product and receive almost no structured data on patient outcomes, real-world usage, or provider-level performance.
"Rinnova creates a dual-sided platform that becomes the system of record for aesthetic treatments — enabling transparency, continuity, and personalized care across providers, patients, and the brands that supply them."
What was done, when, how much, by whom — captured at every visit.
A single timeline that follows the patient across providers and years.
Data-driven product and cadence recommendations unique to each patient.
Ongoing provider–client relationship between visits, not just during them.
Embedded commerce, retention tools, and industry-first real-world data.
Rinnova is designed from day one to serve the patient, the provider, and the manufacturer — creating compounding value the longer everyone uses it.
See everything your provider does, with the clarity you'd expect from any modern health app.
Purpose-built for aesthetic practices — not adapted from a generic EMR. Drive rebookings and see your practice clearly.
Real-world performance data across providers, geographies, and patient segments — a category first.
A structurally underserved market growing at ~15% a year, with no purpose-built infrastructure layer and an aging EMR ecosystem that wasn't designed for it.
Sources: Grand View Research, MarketsandMarkets, AmSpa, ASPS, IBISWorld (2024–2026). SOM is illustrative.
Walk through all three sides — patient, provider, manufacturer — with a live prototype that works on any device. No signup. No install. Just click through every screen.